Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis
Objectives To systematically review and meta-analyse the evidence for effect modification by refractory status and number of treatment lines in relapsed/refractory multiple myeloma (RRMM); and to assess whether effect modification is likely to invalidate network meta-analyses (NMA) that assume negli...
Saved in:
| Main Authors: | Atle Fretheim, Christopher James Rose, Ingrid Kristine Ohm, Liv Giske, Gunn Eva Næss |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-08-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/13/8/e067966.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
by: Adrian Schmidt
Published: (2023-10-01) -
Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01) -
Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Claudio Cerchione, et al.
Published: (2016-01-01) -
Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
by: Yi L, et al.
Published: (2024-11-01) -
The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone
by: Hitomi Nakayama, et al.
Published: (2024-09-01)